An interventional study of Vitamin B12 + folic acid supplementation and Placebo supplementation in Overweight and Obesity and Lupus Erythematosus, sponsored by University of Sao Paulo. Enrolling by invitation at 1 site in Brazil. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Obesity by University of Sao Paulo — 5 open to participants now, 11 under way, none of them phase 3. Obesity · University of Sao Paulo.
Among the 42 studies in Obesity by University of Sao Paulo, this one is the 12th largest by planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 28th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 42 studies in Obesity by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 10–14
University of Sao Paulo · Sites in Brazil
Ages 18–70
University of Sao Paulo · Sites in Brazil
Ages 18–45 · Women only
University of Sao Paulo
Ages 60–75 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 51 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 40 across the 35 interventional studies, 40 across the 7 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Obesity by University of Sao Paulo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07730255University of Sao PauloExercise and Taurine Supplementation on Intramuscular Fat in Older Women With Obesity | 2026-12 |
| NCT07466069University of Sao PauloLifestyle Intervention for Obesity and Eating Disorder Prevention in Transgender Adolescents | 2026-12 |
| NCT07910747University of Sao PauloEffects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Obesity by University of Sao Paulo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dietary supplementation with methyl donors has been demonstrated to increase DNA methylation in leucocytes whereas a limited dietary intake of methyl donors was associated with DNA hypomethylation. Considering SLE disease, previously study showed that high doses of vitamin B6 and folate were associated with less severe SLE. Furthermore, some evidences reported a relatively high incidence of decreased serum B12 levels in rheumatic patients. This led to the suggestion that diets rich in methyl group donors could have beneficial effects on SLE.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 51 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive supplementation.
Dietary Supplement: Vitamin B12 + folic acid supplementation
Patients with excess body weight (BMI \> 25 kg/m²) that will receive supplementation.
Dietary Supplement: Vitamin B12 + folic acid supplementation
Patients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive placebo.
Dietary Supplement: Placebo supplementation
Patients with excess body weight (BMI \> 25 kg/m²) that will receive placebo.
Dietary Supplement: Placebo supplementation
A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
Change from baseline on DNA methylation profile at 12 weeks
Percentage of DNA methylation level
Time frame: Baseline and 12 weeks
Change from baseline on weight at 12 weeks
Weight in kilograms
Time frame: Baseline and 12 weeks
Change from baseline on serum vitamin B12 concentrations at 12 weeks
Serum vitamin B12 concentrations in pg/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum folic acid concentrations at 12 weeks
Serum folic acid concentrations in ng/mL
Time frame: Baseline and 12 weeks
Age of onset
Units of Measure: years
Time frame: Baseline
Duration of disease since diagnosis
Units of Measure: years
Time frame: Baseline
Change from baseline on miR-146 expression at 12 weeks
Relative miR-146 expression
Time frame: Baseline and 12 weeks
Change from baseline on miR-181 expression at 12 weeks
Relative miR-181 expression
Time frame: Baseline and 12 weeks
Change from baseline on miR-21 expression at 12 weeks
Relative miR-21 expression
Time frame: Baseline and 12 weeks
Change from baseline on miR-126 expression at 12 weeks
Relative miR-126 expression
Time frame: Baseline and 12 weeks
Change from baseline on TNF-a gene expression at 12 weeks
Relative gene expression of TNF-a
Time frame: Baseline and 12 weeks
Change from baseline on LEP gene expression at 12 weeks
Relative gene expression of LEP
Time frame: Baseline and 12 weeks
Change from baseline on ADIPOQ gene expression at 12 weeks
Relative gene expression of ADIPOQ
Time frame: Baseline and 12 weeks
Change from baseline on MTHFR gene expression at 12 weeks
Relative gene expression of MTHFR
Time frame: Baseline and 12 weeks
Change from baseline on STAT3 gene expression at 12 weeks
Relative gene expression of STAT3
Time frame: Baseline and 12 weeks
Change from baseline on IL-6 gene expression at 12 weeks
Relative gene expression of IL-6
Time frame: Baseline and 12 weeks
Change from baseline on DNMT1 gene expression at 12 weeks
Relative gene expression of DNMT1
Time frame: Baseline and 12 weeks
Change from baseline on serum leptin concentrations at 12 weeks
Serum leptin concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum IL-6 concentrations at 12 weeks
Serum IL-6 concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum IL-17 concentrations at 12 weeks
Serum IL-17 concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum IL-2 concentrations at 12 weeks
Serum IL-2 concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum TNF-a concentrations at 12 weeks
Serum TNF-a concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum C-reactive protein concentrations at 12 weeks
Serum C-reactive protein concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum adipokines concentrations at 12 weeks
Serum adipokines concentration in ng/mL
Time frame: Baseline and 12 weeks
Change from baseline on serum triglycerides concentrations at 12 weeks
Serum triglycerides concentration in mg/dL
Time frame: Baseline and 12 weeks
Change from baseline on serum cholesterol concentrations at 12 weeks
Serum cholesterol concentrations in mg/dL
Time frame: Baseline and 12 weeks
Change from baseline on serum glucose concentrations at 12 weeks
Serum glucose concentrations in mg/dL
Time frame: Baseline and 12 weeks
Change from baseline on dietary intake at 12 weeks
Dietary intake in g and percentage
Time frame: Baseline and 12 weeks
Change from baseline on abdominal circumference at 12 weeks
Abdominal circumference in centimeters
Time frame: Baseline and 12 weeks
Change from baseline on fat mass at 12 weeks
Fat mass in kilograms
Time frame: Baseline and 12 weeks
Change from baseline on fat free mass at 12 weeks
Fat free mass in kilograms
Time frame: Baseline and 12 weeks
Change from baseline on body mass index at 12 weeks
Body mass index in kilograms/meters\^2
Time frame: Baseline and 12 weeks
Change from baseline on height at 12 weeks
Height in meters
Time frame: Baseline and 12 weeks
Ran from Jan 2022 to primary completion in Jul 2022, 6 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.